Last reviewed 2026-04-22 · How we verify

Teriparatide Pen Injector

Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling.

Teriparatide is a recombinant parathyroid hormone analog that stimulates osteoblasts to increase bone formation and remodeling. Used for Osteoporosis in postmenopausal women and men at high risk of fracture, Glucocorticoid-induced osteoporosis.

At a glance

Mechanism of action

Teriparatide mimics the action of endogenous parathyroid hormone (PTH) by binding to PTH1 receptors on osteoblasts, promoting bone anabolism and increasing bone mineral density. Unlike continuous PTH exposure which causes bone loss, intermittent administration of teriparatide preferentially stimulates bone formation over resorption, leading to net increases in bone mass and strength.

Approved indications

• Osteoporosis in postmenopausal women and men at high risk of fracture
• Glucocorticoid-induced osteoporosis

Common side effects

• Injection site reactions (erythema, pain, swelling)
• Nausea
• Dizziness
• Headache
• Hypercalcemia
• Leg cramps

Key clinical trials

• Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid (PHASE4)
• The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA (PHASE3)
• Teriparatide on Maxillary Sinus Floor Osseointegration (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Teriparatide Pen Injector CI brief — competitive landscape report
• Teriparatide Pen Injector updates RSS · CI watch RSS
• University of Edinburgh portfolio CI